Silo Pharma (SILO) Non-Current Assets (2018 - 2026)
Silo Pharma (SILO) posted Non-Current Assets of $214438.0 for Q1 2026, down 1.35% sequentially from $217375.0 in Q4 2025, and down 27.51% YoY from $295808.0 in Q1 2025.
Silo Pharma (SILO) Non-Current Assets (2018 - 2026) Analysis & Trends
Silo Pharma has reported Non-Current Assets for 9 years, with the latest figure at $214438.0 in Q1 2026.
- Quarterly Non-Current Assets fell 27.51% year-over-year to $214438.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $214438.0 (down 27.51% YoY) and the FY2025 annual result came in at $217375.0, down 27.63% from the prior year.
- Non-Current Assets eased to $214438.0 in Q1 2026 per SILO's latest filing, from $217375.0 in the prior quarter.
- Over five years, Non-Current Assets peaked at $309464.0 in Q2 2024 and troughed at $63523.0 in Q1 2024.
- A 5-year average of $169246.2 and a median of $137085.0 in 2022 frame the typical range for Non-Current Assets.
- The sharpest annual moves came in 2022 and 2023: Non-Current Assets soared 403.71% in 2022, then sank 51.53% in 2023.
- Over 5 years, Non-Current Assets stood at $70821.0 in 2022, then retreated by 8.24% to $64983.0 in 2023, then jumped by 362.21% to $300360.0 in 2024, then slipped by 27.63% to $217375.0 in 2025, then slipped by 1.35% to $214438.0 in 2026.
- According to Business Quant data, Non-Current Assets over the past three periods registered $214438.0, $217375.0, and $220312.0 for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 14.88 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 23.28 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.96 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 5.15 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 1.96 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 938.60 Mn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 468.65 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 18.06 Bn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 6.80 Bn |
| 10 | Silo Pharma | 3.04 Mn | 3.04 Mn | - | 238,497.00 |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 238,497.00 |
| Mar 31, 2026 | 214,438.00 |
| Dec 31, 2025 | 217,375.00 |
| Sep 30, 2025 | 220,312.00 |
| Jun 30, 2025 | 279,476.00 |
| Mar 31, 2025 | 295,808.00 |
| Dec 31, 2024 | 300,360.00 |
| Sep 30, 2024 | 304,912.00 |
| Jun 30, 2024 | 309,464.00 |
| Mar 31, 2024 | 63,523.00 |
| Dec 31, 2023 | 64,983.00 |
| Sep 30, 2023 | 66,442.00 |
| Jun 30, 2023 | 67,902.00 |
| Mar 31, 2023 | 69,361.00 |
| Dec 31, 2022 | 70,821.00 |
| Sep 30, 2022 | 137,085.00 |
| Jun 30, 2022 | 97,330.00 |
| Mar 31, 2022 | 97,593.00 |
| Dec 31, 2021 | 87,869.00 |
| Sep 30, 2021 | 88,118.00 |